secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0000950170-23-065482
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma promotes Jane Chung to President and COO effective Dec 1, 2023
------------------------------------------------------------------------------

- Jane Chung, previously Chief Commercial Officer, appointed President and COO, a newly created role.
- New compensation includes $560k base salary, up to 50% bonus, 35k stock options, and 100k RSUs.
- Chung previously served as President/GM of AstraZeneca Canada and VP of Immuno-Oncology at AstraZeneca.
- Role focuses on operational excellence, strategic growth, and cross-functional alignment across R&D and portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/0000950170-23-065482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/stro-20231121.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-065482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer